
DKSH Management Ltd.
/ Key word(s): Takeover
Media release DKSH has signed an agreement to acquire Molecular Diagnostics Korea Inc. ("MDxK"), a well- established player in the South-Korean life-science space. With this transaction, DKSH Technology further extends its scientific solutions business in line with the Business Unit's strategy to solidify its position as a leading scientific solutions provider in Asia and Beyond. Zurich, Switzerland, March 26, 2025 - DKSH has announced today that it signed an agreement to acquire MDxK, a well-established South Korean provider of advanced scientific solutions. MDxK specializes in providing state-of-the-art solutions for molecular diagnostics, cellular analysis, structural biology, and biobanking. The acquisition of MDxK further strengthens the Business Unit's position in the molecular diagnostics market, further complementing its scientific workflow solutions and solidifying its position in the life science sector in South Korea. About DKSH For more information please contact: DKSH Holding Ltd. Melanie Grüter End of Media Release |
Language: | English |
Company: | DKSH Management Ltd. |
Wiesenstrasse 8 | |
8008 Zurich | |
Switzerland | |
Phone: | 044 386 72 72 |
E-mail: | media@dksh.com |
Internet: | www.dksh.com |
ISIN: | CH0126673539 |
Valor: | 12667353 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 2106364 |
End of News | EQS News Service |
2106364 26.03.2025 CET/CEST